Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.

Abrunhosa-Branquinho, André N

Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. [electronic resource] - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology May 2018 - 292-298 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1879-0887

10.1016/j.radonc.2018.03.013 doi


Antineoplastic Agents, Alkylating--therapeutic use
Brain Neoplasms--drug therapy
Chemotherapy, Adjuvant
Chromosome Deletion
Chromosomes, Human, Pair 1
Chromosomes, Human, Pair 19
Dacarbazine--analogs & derivatives
Glioma--drug therapy
Humans
Prospective Studies
Quality Assurance, Health Care
Radiotherapy Planning, Computer-Assisted--methods
Retrospective Studies
Temozolomide
Tomography, X-Ray Computed--methods